Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kyowa Hakko Kirin Schedules Production Of Japan’s Second Antibody Drug

This article was originally published in PharmAsia News

Executive Summary

Kyowa Hakko Kirin of Japan has scheduled 2013 production of an antibody-based leukemia drug still in testing phases, and is beefing up its production capacity to do so. The company is betting on a paucity of drugs based on the technology, so it plans to spend more than $105 million to build a production wing at one of its plants and add to other infrastructure. The company also has an antibody-based drug in the testing phase for treating stomach cancers, but the leukemia is expected to be the first approved if clinical trials proceed as planned. The firm also is developing a similar drug with Astellas Pharma for suppressing the immune system during organ transplants. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts